Physician profile
Gabriel Sayer
NPI 1740405836
$94,730.11
in general payments reported to CMS, 2019-2025
37 companies · $34K in 2025
The $34K reported for 2025 was more than what 89% of Advanced Heart Failure and Transplant Cardiology providers received nationally (typical 2025 total: $1,046).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,445 · 2020: $1,336 · 2021: $4,795 · 2022: $12K · 2023: $12K · 2024: $22K · 2025: $34K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $28K · Travel and Lodging: $20K · Food and Beverage: $16K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,069 · Education: $18.09.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $27,568.75 |
| Travel and Lodging | $19,914.69 |
| Food and Beverage | $15,944.80 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,068.75 |
| Education | $18.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $80,339.65 | 2019-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Cardiomems, 2nd Gen Centrimag Primary Console |
| Abiomed | $3,596.23 | 2022-2025 | Impella |
| Transmedics, INC. | $2,767.21 | 2021-2025 | Organ Care System |
| Medtronic Vascular, INC. | $1,500.62 | 2019-2020 | |
| Ancora Heart, INC. | $1,199.50 | 2021-2025 | Accucinch |
| One Lambda, INC. | $1,166.95 | 2024 | |
| Cvrx, INC. | $837.91 | 2023-2025 | Barostim Neo System |
| Novartis Pharmaceuticals Corporation | $675.97 | 2022-2025 | |
| Procyrion, INC. | $324.95 | 2023-2025 | Aortix System |
| Opsens INC. | $283.44 | 2022 | |
| Paragonix Technologies, INC. | $247.69 | 2024 | Pancreaspak, Liverguard, Lungguard |
| Merck Sharp & Dohme LLC | $236.90 | 2022-2025 | Verquvo, Winrevair |
| Boehringer Ingelheim Pharmaceuticals, INC. | $196.94 | 2021-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $166.37 | 2020-2025 | Wainua, Farxiga |
| Itamar Medical INC | $135.22 | 2023-2025 | Watchpatone |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Elutia, INC. | $116.66 | 2021 | |
| Endotronix, INC. | $107.78 | 2025 | Cordella Pulomonary Artery Pressure Sensor |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $104.60 | 2019-2025 | Lifevest |
| Alnylam Pharmaceuticals INC. | $98.42 | 2022-2025 | Amvuttra, Onpattro |
| Kiniksa Pharmaceuticals International, Plc | $91.45 | 2024 | Arcalyst |
| Edwards Lifesciences Corporation | $76.27 | 2022 | |
| Bridgebio Pharma, INC. | $58.87 | 2025 | Attruby |
| United Therapeutics Corporation | $57.93 | 2019 | |
| Daiichi Sankyo INC. | $43.51 | 2023 | Injectafer |
| E.R. Squibb & Sons, L.L.C. | $41.15 | 2025 | Camzyos |
| Scpharmaceuticals INC. | $36.81 | 2025 | |
| Lexicon Pharmaceuticals, INC. | $36.33 | 2023-2024 | Inpefa |
| Vifor Pharma, INC. | $32.55 | 2019 | |
| Amgen INC. | $31.73 | 2022-2025 | Repatha |
| Portola Pharmaceuticals, LLC | $26.83 | 2019 | |
| Lilly USA, LLC | $26.13 | 2025 | Zepbound |
| Medtronic, INC. | $24.08 | 2021 | |
| Nihon Kohden America, LLC | $18.35 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $12.83 | 2019 | |
| Pfizer INC. | $12.28 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gabriel Sayer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.